Molecular testing for use at home and the point of care has boomed in the wake of the COVID-19 pandemic, and sexually transmitted infections have been a key area of focus for test developers and manufacturers after respiratory testing. Companies large and small have emphasized the importance of molecular point-of-care STI testing.
Now that molecular point-of-care testing technology has continued to advance, what are test users looking for in their tests and platforms, particularly when it comes to turnaround time or multiplexing? Where should test developers focus their efforts? How does molecular testing at both the point-of-care and at home fit in with other options for testing? What changes are on the horizon in the next three years as technology continues to develop?
In this virtual roundtable, our panel of experts on sexually transmitted infections and molecular point-of-care testing will discuss these questions.
